ديجيتال فابلت

الوسم: early treatment

  • Early Amyloid Clearance Could Delay Alzheimer’s Progression

    Early Amyloid Clearance Could Delay Alzheimer’s Progression

    Credit: Unsplash+

    Alzheimer’s disease is the leading cause of dementia, impacting millions globally. It gradually erases memory, hampers thinking, and makes everyday tasks difficult. Despite decades of research, many questions remain about its origins and how to slow its progression.

    Two proteins are central to Alzheimer’s research.

    One is beta-amyloid, which forms sticky plaques outside neurons. The other is tau, which creates tangled fibers inside brain cells. These abnormal proteins are believed to damage and eventually kill nerve cells in the brain.

    Recently, new medications that remove amyloid plaques have transformed Alzheimer’s treatment. Drugs like lecanemab and donanemab assist the immune system in clearing amyloid deposits from the brain.

    Earlier drugs, such as aducanumab, demonstrated that plaque removal is possible, but experts continue debating whether eliminating amyloid also slows the disease’s core processes and offers long-term protection for brain cells.

    A groundbreaking study from the Perelman School of Medicine at the University of Pennsylvania offers some of the strongest evidence so far that clearing amyloid plaques might also reduce tau buildup, which is more closely linked to memory loss and neuronal damage.

    The findings were shared at the 2026 Alzheimer’s Association International Conference and published simultaneously in JAMA.

    The research was made possible by examining the brain of a man in his fifties who participated in an Alzheimer’s clinical trial before passing away. Diagnosed with mild cognitive impairment due to Alzheimer’s, he received an anti-amyloid treatment during the study.

    Microscopic examination revealed an unusual pattern: some brain areas were nearly free of amyloid plaques, while adjacent regions still contained large amounts. This presented a rare chance to compare neighboring areas with different levels of treatment success.

    The contrast was striking. Regions where amyloid was effectively cleared showed very little tau and signs of ongoing damage. Conversely, nearby areas with remaining amyloid exhibited higher tau levels, increased inflammation, and more nerve cell injury.

    Since both tissue samples came from the same individual, the comparison minimized differences that typically exist between patients.

    This supports the idea that amyloid accumulation might initiate a cascade that promotes tau spread throughout the brain. Removing amyloid early could potentially break this chain, slowing or halting disease progression.

    Researchers believe this could explain why benefits from anti-amyloid treatments tend to become more apparent over time. Most trials last about 18 months, but reducing tau buildup over several years may lead to more meaningful improvements, as brain damage advances more slowly.

    Scientists are eager to learn why some brain regions clear amyloid more effectively than others. Improving plaque removal across the entire brain could make future therapies even more successful.

    It’s important to note this study doesn’t prove that amyloid removal alone can cure Alzheimer’s. It’s based on a single case, so larger studies are necessary to confirm these findings. Still, it provides rare, direct human evidence supporting one of the leading theories of the disease.

    This research also highlights the importance of early intervention. Amyloid begins accumulating years before symptoms appear. If future evidence shows that earlier removal delays or prevents dementia, early diagnosis and treatment will become even more crucial.

    While this case is promising, it’s important to recognize its limitations. As it involved only one person, it can’t establish cause and effect or predict outcomes for everyone. Nevertheless, the results suggest that early, aggressive amyloid removal might slow disease processes and yield greater long-term benefits.

    If you’re interested in Alzheimer’s research, consider exploring studies linking vitamin D deficiency to the disease or the potential of strawberries as a natural defense.

    For additional health insights, look into recent research on foods that may lower Alzheimer’s risk and studies indicating that oral cannabis extracts could help manage symptoms.

    Source: University of Pennsylvania Perelman School of Medicine.

  • Pre-Treatment Drug Can Delay Arthritis Onset for Years

    Pre-Treatment Drug Can Delay Arthritis Onset for Years

    Credit: Unsplash+

    Many individuals report that rheumatoid arthritis appears suddenly, with some experiencing painful, swollen joints, extreme fatigue, and stiffness that interfere with daily routines.

    However, researchers now understand that the disease often begins developing long before any diagnosis is made.

    A recent study from King’s College London indicates that early intervention might greatly postpone the onset of rheumatoid arthritis. Published in The Lancet Rheumatology, the study found that a year-long treatment with the drug abatacept delayed rheumatoid arthritis in those at high risk.

    This research is particularly significant because there are currently no approved treatments aimed specifically at preventing rheumatoid arthritis. Most therapies are administered after the disease has already caused joint damage.

    Rheumatoid arthritis is an autoimmune disorder. In autoimmune conditions, the immune system mistakenly attacks healthy tissues instead of defending the body from infections.

    With rheumatoid arthritis, the immune system primarily targets the joints, leading to inflammation, pain, swelling, and stiffness. Prolonged inflammation can damage cartilage and bones, ultimately causing disability and lowering quality of life.

    The condition affects hundreds of thousands in the U.S. and millions globally. While it can occur at any age, it typically develops during middle age. Many individuals endure years of pain, fatigue, and difficulty performing everyday tasks or working.

    Scientists have recently started focusing on identifying people who are likely to develop rheumatoid arthritis before symptoms become severe.

    Certain blood tests detect antibodies that can appear years prior to diagnosis. These serve as warning signs that the immune system might be heading in the wrong direction.

    The study tracked 213 participants from the U.S. and the Netherlands, all considered at high risk of developing rheumatoid arthritis. Some received abatacept for a year, while others received a placebo.

    Abatacept is a biologic medication that modulates immune activity. It’s already approved for treating established rheumatoid arthritis, but researchers wanted to explore whether it could be effective earlier in the disease process.

    The original trial lasted two years, but the new research extended follow-up to between four and eight years, making it one of the longest studies of its kind in high-risk individuals.

    The results showed promising trends. Participants on abatacept developed rheumatoid arthritis much later than those on placebo. In some cases, the delay was up to four years after stopping treatment.

    While abatacept didn’t fully prevent the disease, postponing its onset by several years could have meaningful benefits, such as less pain, reduced disability, and fewer disruptions to work and family life.

    The biggest benefits were observed in participants at the highest risk, identified through blood tests detecting disease-related antibodies. Interestingly, those most likely to develop rheumatoid arthritis also gained the most from treatment.

    Participants reported improvements in symptoms—including joint pain, fatigue, and overall wellbeing—during treatment. However, these benefits tended to diminish after stopping the medication, suggesting continuous treatment might be necessary to sustain symptom relief.

    The study also confirmed that the treatment is relatively safe, with serious side effects occurring at similar rates in both the abatacept and placebo groups. No new safety concerns emerged during long-term follow-up.

    This research offers compelling evidence that autoimmune diseases can potentially be modified before they fully manifest. The extended follow-up strengthens the findings, showing that some benefits may persist even after treatment stops.

    However, since abatacept only delayed rather than prevented rheumatoid arthritis, additional studies are needed to determine whether longer or different treatments could offer better protection.

    The findings support a growing emphasis on early detection and intervention—aiming to prevent irreversible joint damage before it occurs.

    If you’re interested in arthritis, consider exploring studies on natural remedies like extra virgin olive oil or pomegranate, which show potential benefits for managing rheumatoid arthritis.

    For more insights, look into recent research on living pain-free with arthritis and how options like medical cannabis may help alleviate arthritis and back pain.

    Source: King’s College London.